Mechanisms of Antithrombotic Drugs

Advances in Pharmacology

Volumn 46, Issue C, 1999, Pages 297-324

  Thiagarajan, Perumal ^a   Wu, Kenneth K ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; FIBRINOLYTIC AGENT; HEPARIN; HIRUDIN DERIVATIVE; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PEPTIDE FRAGMENT; PURINE P2 RECEPTOR; RECOMBINANT PROTEIN; VITAMIN K GROUP;

ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; HEMOSTASIS; HUMAN; REVIEW; THROMBOSIS;

ANIMALS; FIBRINOLYTIC AGENTS; HEMOSTASIS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HIRUDINS; HUMANS; PEPTIDE FRAGMENTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECEPTORS, PURINERGIC P2; RECOMBINANT PROTEINS; THROMBOSIS; VITAMIN K;

EID: 0032619358     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(08)60474-3     Document Type: Chapter

References (129)

1. Agnelli G., and Sonaglia F. Recombinant hirudin in the prevention of venous thromboembolism in patients undergoing elective hip surgery. Semin. Thromb. Hemost. 23 (1997) 143-148
2. Akkerman J.W., and van Willigen G. Platelet activation via trimeric GTP-binding proteins. Haemostasis 26 (1996) 199-209
3. Almquist H.J. The early history of vitamin K. Am. J. Clin. Nutr. 28 (1975) 656-659
4. Alving B.M., and Krishnamurti C. Recognition and management of heparin-induced thrombocytopenia (HIT) and thrombosis. Semin. Thromb. Hemost. 23 (1997) 569-574
5. Amiral J., Bridey F., Wolf M., Boyer-Neumann C., Fressinaud E., Vissac A.M., Peynaud-Debayle E., Dreyfus M., and Meyer D. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: A study of 44 cases. Thromb. Haemost. 73 (1995) 21-28
6. Ancalmo N., and Ochsner J. Heparin, the miracle drug: A brief history of its discovery. J. La. State Med. Soc. 142 (1990) 22-24
7. Andersen K., and Dellborg M. Heparin is more effective than inogatran, a low-molecular weight thrombin inhibitor in suppressing ischemia and recurrent angina in unstable coronary disease: Thrombin Inhibition in Myocardial Ischemia (TRIM) Study Group. Am. J. Cardiol. 81 (1998) 939-944
8. Andrews R.K., Lopez J.A., and Berndt M.C. Molecular mechanisms of platelet adhesion and activation. Int. J. Biochem. Cell Biol. 29 (1997) 91-105
9. Anonymous. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients: Antiplatelet Trialists' Collaboration. Brit Med J. 308 (1994) 81-106
10. Anonymous. Collaborative overview of randomised trials of antiplatelet therapy. II. Maintenance of vascular graft or arterial patency by antiplatelet therapy: Antiplatelet Trialists' Collaboration. Brit Med J. 308 (1994) 159-168
11. Anonymous. Collaborative overview of randomised trials of antiplatelet therapy. III. Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients: Antiplatelet Trialists' Collaboration. Brit Med J. 308 (1994) 235-246
12. Antman E.M. Hirudin in acute myocardial infarction: Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 90 (1994) 1624-1630
13. Antman E.M., and Handin R. Low-molecular-weight heparins: An intriguing new twist with profound implications. Circulation 98 (1998) 287-289
14. Armstrong R.A. Platelet prostanoid receptors. Pharmacol. Ther. 72 (1996) 171-191
15. Ashby B. Novel mechanism of heterologous desensitization of adenylate cyclase: Prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets. Mol. Pharmacol. 38 (1990) 46-53
16. Bates E.R. Clinical trial results with hirudin and bivalirudin for acute coronary artery syndromes. Semin. Thromb. Hemost. 23 (1997) 575-581
17. Becker D.L., Fredenburgh J.C., Stafford A.R., and Weitz J.I. Molecular basis for the resistance of fibrin-bound thrombin to inactivation by heparin/serpin complexes. Adv. Exp. Med. Biol. 425 (1997) 55-66
18. Bittl J.A. Clinical trials of Hirulog in patients undergoing high-risk percutaneous transluminal coronary angioplasty. Coron. Artery Dis. 7 (1996) 449-454
19. Blockmans D., Deckmyn H., and Vermylen J. Platelet activation. Blood 9 (1995) 143-156
20. Borris L.C., and Lassen M.R. A comparative review of the adverse effect profiles of heparins and heparinoids. Drug Saf. 12 (1995) 26-31
21. Bovill E.G., and Mann K. Warfarin and the biochemistry of the vitamin K dependent proteins. Adv. Exp. Med. Biol. 214 (1987) 17-46
22. Bracht F., and Schror K. Isolation and functional characterization of DNA-derived aptamers that act as thrombin inhibitors in human platelets and coagulation assays. Agents Actions 45 Suppl. (1995) 315-322
23. Brass L.F. Thrombin receptor antagonists: A work in progress. Coron. Artery Dis. 8 (1997) 49-58
24. Brass L.F., Manning D.R., Cichowski K., and Abrams C.S. Signaling through G proteins in platelets: To the integrins and beyond. Thromb. Haemost. 78 (1997) 581-589
25. Broze Jr. G.J. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu. Rev. Med. 46 (1995) 103-112
26. Cable D.G., O'Brien T., Schaff H.V., and Pompili V.J. Recombinant endothelial nitric oxide synthase-transduced human saphenous veins: Gene therapy to augment nitric oxide production in bypass conduits. Circulation 96 (1997) 173-178
27. Campbell H.A., and Link K.P. Studies on hemorrhagic sweet clover disease: Isolation and crystalization of the hemorrhagic agent. J. Biol. Chem. 138 (1929) 21-33
28. Cattaneo M., Lombardi R., Bettega D., Lecchi A., and Mannucci P.M. Shear induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine. Arterioscler. Thromb. 13 (1993) 393-397
29. Chesebro J.H. Direct thrombin inhibition superior to heparin during and after thrombolysis: Dose, duration and drug. Circulation 96 (1997) 2118-2120
30. Chen Y., Pitzenberger S.M., Garsky V.M., Lumma P.K., Sanyal G., and Baum J. Proton NMR assignments and secondary structure of the snake venom protein echistatin. Biochemistry 30 (1991) 11625-11636
31. Choay J. Structure and activity of heparin and its fragments: An overview. Semin. Thromb. Hemost. 15 (1989) 359-364
32. Church F.C., Phillips J.E., and Woods J.L. Chimeric antithrombin peptide. Characterization of an Arg-Gly-Asp (RGD)- and hirudin carboxyl terminus-containing synthetic peptides. J. Biol. Chem. 266 (1991) 11975-11979
33. Coller B.S. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein Ilb/IIIa complex. J. Clin. Invest. 76 (1985) 101-108
34. Coller B.S. Blockade of platelet GPIIb/IIIa receptors as an antithrombotic strategy. Circulation 92 (1995) 2373-2380
35. Dam H. Cholesterinstoffwechsel in Huhneriern and Hunchen. Biochem. Zeit 215 (1929) 475-492
36. Danielsson A., Raub E., Lindahl U., and Bjork I. Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J. Biol. Chem. 261 (1986) 15467-15473
37. Davie E.W., Fujikawa K., and Kisiel W. The coagulation cascade: Initiation, maintenance and regulation. Biochemistry 30 (1991) 10363-10370
38. Dery O., Corvera C.U., Steinhoff M., and Bunnett N.W. Proteinase-activated receptors: Novel mechanisms of signaling by serine proteases. Am. J. Physiol. C274 (1998) 1429-1452
39. Edgington T.S., Dickinson C.D., and Ruf W. The structural basis of function of the TF-VIIa complex in the cellular initiation of coagulation. Thromb. Haemost. 78 (1997) 401-405
40. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and lowdose heparin during percutaneous coronary revascularization. N. Engl J. Med. 336 (1997) 1689-1696
41. Gent M. CAPRIE steering committee: A randomized, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events. Lancet 348 (1996) 1329-1339
42. Ginsberg J.S., Nurmohamed M.T., Gent M., MacKinnon B., Sicurella J., Brill-Edwards P., Levine M.N., Panju A.A., Powers P., Stevens P., et al. Use of Hirulog in the prevention of venous thrombosis after major hip or knee surgery. Circulation 90 (1994) 2385-2389
43. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 90 (1994) 1631-1637
44. Glusa E. Pharmacology and therapeutic applications of hirudin, a new anticoagulant. Kidney Int. 64 (1998) S54-S56
45. Gould R.J., Polokoff M.A., Friedman P.A., Huang T.F., Holt J.C., Cook J.J., and Niewiarowski S. Disintegrins: A family of integrin inhibitory proteins from viper venoms. Proc. Soc. Exp. Biol. Med. 195 (1990) 168-171
46. Grant S.M., and Goa K.L. Iloprost: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures. Drugs 43 (1992) 889-924
47. Gresele P., Deckmyn H., Nenci G.G., and Vermylen J. Thromboxane synthase inhibitors, thromboxane receptor antagonists and dual blockers in thrombotic disorders. Trends Pharmacol. Sci. 12 (1991) 158-166
48. Harenberg J., Schneider D., Heilmann L., and Wolf H. Lack of anti-factor Xa activity in umbilical cord vein samples after subcutaneous administration of heparin or low molecular mass heparin in pregnant women. Haemostasis 23 (1993) 314-320
49. Hartman G.D., Egbertson M.S., Halczenko W., Laswell W.L., Duggan M.E., Smith R.L., Naylor A.M., Manno P.D., Lynch R.J., and Zhang G. Non-peptide fibrinogen receptor antagonists. 1. Discovery and design of exosite inhibitors. J. Med. Chem. 35 (1992) 4640-4642
50. Hass W.K., Easton J.D., Adams H.P., Pryse-Phillips W., Molony B.A., Anderson S., and Kamm B. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients: Ticlopidine Aspirin Stroke Study. N. Engl J. Med. 321 (1989) 501-507
51. Hirsh J. Optimal intensity and monitoring warfarin. Am. J. Cardiol. 75 (1995) 39B-42B
52. Hirsh J., Dalen J.E., Deykin D., Poller L., and Bussey H. Oral anticoagulants. Mechanism of action, clinical effectiveness and optimal therapeutic range. Chest 108 (1995) 231S-246S
53. Hirsh J., Ofosu F., and Buchanan M. Rationale behind the development of low molecular weight heparin derivatives. Semin. Thromb. Hemost. 11 (1985) 13-16
54. Hursting M.J., Alford K.L., Becker J.C., Brooks R.L., Joffrion J.L., Knappenberger G.D., Kogan P.W., Kogan T.P., McKinney A.A., and Schwarz Jr. R.P. Novastan (brand of argatroban): A small-molecule, direct thrombin inhibitor. Semin. Thromb. Hemost. 23 (1997) 503-516
55. Imanishi T., Arita M., Tomobuchi Y., Hamada M., Hano T., and Nishio I. Effects of locally administered argatroban on restenosis after balloon angioplasty: Experimental and clinical study. Clin. Exp. Pharmacol. Physiol. 24 (1997) 800-806
56. Kakar V.V. Low-molecular weight heparin: Prophylaxis of venous thrombosis. In: Loscalzo S., and Loscalzo J. (Eds). "New Therapeutic Agents in Thrombosis and Thrombolysis" (1997), Marcel Dekker, New York 103-128
57. Kerins D.M., Murray R., and FitzGerald G.A. Prostacyclin and prostaglandin E1: Molecular mechanisms and therapeutic utility. Prog. Hemost. Thromb. 10 (1991) 307-337
58. Kiss J. Hepartin: Chemistry and clinical usage; chemical structure of heparin. In: Kakker V.V., and Thomas D.P. (Eds). "Heparin: Chemistry and Clinical Usage" (1977), Academic Press, London 3-20
59. Krishnan R., Zhang E., Hakansson K., Arni R.K., Tulinsky A., Lim-Wilby M.S., Levy O.E., Semple J.E., and Brunck T.K. Highly selective mechanism-based thrombin inhibitors: Structures of thrombin and trypsin inhibited with rigid peptidyl aldehydes. Biochemistry 37 (1998) 12094-12103
60. Lincoff A.M., Califf R.M., Anderson K.M., Weisman H.F., Aguirre F.V., Kleiman N.S., Harrington R.A., and Topol E.J. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization: EPIC Investigators: Evaluation of 7E3 in preventing Ischemic Complications. J. Am. Coll. Cardiol. 30 (1997) 149-156
61. Linet O.L., and Mohberg N.R. Therapeutic effectiveness of prostaglandins (PGs) in peripheral vascular disease (PVD). Adv. Prostaglandin Thromboxane Leukot. Res. 19 (1989) 307-310
62. Lopez J.A. The platelet glycoprotein Ib-IX complex. Blood Coagul. Fibrinolysis 5 (1994) 97-119
63. Love B.B., Biller J., and Gent M. Adverse haematological effects of ticlopidine: Prevention, recognition and management. Drug Saf. 19 (1998) 89-98
64. Magnusson S., Sottrup-Jensen L., Petersen T.E., Morris H.R., and Dell A. Primary structure of the vitamin K-dependent part of prothrombin. FEBS Lett. 44 (1974) 189-193
65. Mann K.G., Krishnaswamy S., and Lawson J.H. Surface-dependent hemostasis. Semin. Hematol. 29 (1992) 213-226
66. Maraganore J.M. Pre-clinical and clinical studies on Hirulog: A potent and specific direct thrombin inhibitor. Adv. Exp. Med. Biol. 340 (1993) 227-236
67. Maraganore J.M., Bourdon P., Jablonski J., Ramachandran K.L., and Fenton II J.W. Design and characterization of hirulogs: A novel class of bivalent peptide inhibitors of thrombin. Biochemistry 29 (1990) 7095-7101
68. Marki W.E., Grossenbacher H., Grutter M.G., Liersch M.H., Meyhack B., and Heim J. Recombinant hirudin: Genetic engineering and structure analysis. Semin. Thromb. Hemost. 17 (1991) 88-93
69. Markwardt F. The development of hirudin as an antithrombotic drug. Thromb. Res. 74 (1994) 1-23
70. Matsuo T., Kario K., Kodama K., and Okamoto S. Clinical application of the synthetic thrombin inhibitor, argatroban (MD-805). Semin. Thromb. Hemost. 18 (1992) 155-160
71. Matsuo T., Koide M., and Kario K. Development of argatroban, a direct thrombin inhibitor and its clinical application. Semin. Thromb. Hemost. 23 (1997) 517-522
72. Mayo K.H., Ilyina E., Roongta V., Dundas M., Joseph J., Lai C.K., Maione T., and Daly T.J. Heparin binding to platelet factor-4: An NMR and site-directed mutagenesis study: Arginine residues are crucial for binding. Biochem. J. 312 (1995) 357-365
73. Menache D., Grossman B.J., and Jackson C.M. Antithrombin III: Physiology, deficiency and replacement therapy. Transfusion 32 (1992) 580-588
74. Moake J.L., Turner N.A., Stathopoulos N.A., Nolasco L., and Hellums J.D. Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate and is resistant to aspirin. Blood 71 (1988) 1366-1374
75. Mueller R.L., and Scheidt S. History of drugs for thrombotic disease: Discovery, development and directions for the future. Circulation 89 (1994) 432-449
76. Muller T.H., Weisenberger H., Brickl R., Narjes H., Himmelsbach F., and Krause J. Profound and sustained inhibition of platelet aggregation by Fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist and its orally active prodrug, Lefradafiban, in men. Circulation 96 (1997) 1130-1138
77. Nelsestuen G.L., Zytkovicz T.H., and Howard J.B. The mode of action of vitamin K: Identification of gamma-carboxyglutamic acid as a component of prothrombin. J. Biol. Chem. 249 (1974) 6347-6350
78. Neuhaus K.L., von Essen R., Tebbe U., Jessel A., Heinrichs H., Maurer W., Doring W., Harmjanz D., Kotter V., Kalhammer E., et al. Safety observations from the pilot phase of the randomized r-Hirudin for Improvement of Thrombolysis (HIT-III) study. Circulation 90 (1994) 1638-1642
79. Olschewski H., Walmrath D., Schermuly R., Ghofrani A., Grimminger F., and Seeger W. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Ann. Intern. Med. 124 (1996) 820-824
80. Palatianos G.M., Dewanjee M.K., Smith W., Novak S., Hsu L.C., Kapadvanjwala M., Sfakianakis G.N., and Kaiser G.A. Platelet preservation during cardiopulmonary bypass with iloprost and Duraflo-II heparin-coated surfaces. ASAIO Trans. 37 (1991) 620-622
81. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein Ilb/IIIa inhibitor), heparin, or both in unstable angina: Platelet Ilb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 97 (1998) 2386-2395
82. Patscheke H. Thromboxane A2/prostaglandin H2 receptor antagonists: A new therapeutic principle. Stroke 21 (1990) 139-142
83. Petitou M., Duchaussoy P., Jaurand G., Gourvenec F., Lederman I., Strassel J.M., Barzu T., Crepon B., Herault J.P., Lormeau J.C., Bernat A., and Herbert J.M. Synthesis and pharmacological properties of a close analogue of an antithrombotic pentasaccharide (SR 90107 A/ORG 31540). J. Med. Chem. 40 (1997) 1600-1607
84. Phillips D.R., and Scarborough R.M. Clinical pharmacology of eptifibatide. Am. J. Cardiol. 80 (1997) 11B-20B
85. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N. Engl. J. Med. 338 (1998) 1498-1505
86. (PRISM-PLUS) Study Investigators. Inhibition of the platelet glycoprotein IIb/Illa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction: Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms. N. Engl. J. Med. 338 (1998) 1488-1497
87. Puri R.N., and Colman R.W. ADP-induced platelet activation. Crit. Rev. Biochem. Mol. Biol. 32 (1997) 437-502
88. Qiu X., Padmanabhan K.P., Carperos V.E., Tulinsky A., Kline T., Maraganore J.M., and Fenton II J.W. Structure of the hirulog 3-thrombin complex and nature of the S′ subsites of substrates and inhibitors. Biochemistry 31 (1992) 11689-11697
89. The RAPT Investigators. Randomized trial of ridogrel, a combine thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. Circulation 89 (1994) 588-595
90. Reilly M., and Fitzgerald G.A. Cellular activation by thromboxane A2 and other eicosanoids. Eur. Heart J. 14 (1993) 88-93
91. Reilly T.M., Knabb R.M., Hassell S.M., Bozarth J.M., Forsythe M.S., Mayo M.C., Racanelli A.L., and Mousa S.A. Effect of thrombin inhibitors on platelet functions: Comparative analysis of DuP 714 and hirudin. Blood Coagul. Fibrinolysis 3 (1992) 513-517
92. Rihal C.S., Flather M., Hirsh J., and Yusuf S. Advances in antithrombotic drug therapy for coronary artery disease. Eur. Heart J. 16 (1995) 10-21
93. Rodriguez H.J., and Vanderwielen A.J. Molecular weight determination of commercial heparin sodium USP and its sterile solutions. J. Pharm. Sci. 68 (1979) 588-591
94. Rosenberg R.D. Role of heparin and heparinlike molecules in thrombosis and atherosclerosis. Fed. Proc. Am. Sci. 44 (1985) 404-409
95. Roth G.J., and Calverley D.C. Aspirin, platelets and thrombosis: Theory and practice. Blood 83 (1994) 885-898
96. Ruggeri Z.M., and Ann N.Y. Glycoprotein Ib and von Willebrand factor in the process of thrombus formation. Acad. Sci. 18 (1994) 200-210
97. Rydel T.J., Ravichandran K.G., Tulinsky A., Bode W., Huber R., Roitsch C., and Fenton II J.W. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science 249 (1990) 277-280
98. Rydel T.J., Tulinsky A., Bode W., and Huber R. Refined structure of the hirudin-thrombin complex. J. Mol. Biol. 221 (1991) 583-601
99. Samama M.M., Bara L., and Gouin-Thibault I. New data on the pharmacology of heparin and low molecular weight heparins. Drugs 52 (1996) 8-14
100. Sandset P.M., Abildgaard U., and Larsen M.L. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb. Res. 50 (1988) 803-813
101. Schomig A., Neumann F.J., Kastrati A., Schuhlen H., Blasini R., Hadamitzky M., Walter H., Zitzmann-Roth E.M., Richardt G., Alt E., Schmitt C., and Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 334 (1996) 1084-1089
102. Schror K. Antiplatelet drugs: A comparative review. Drugs 50 (1995) 7-28
103. Schror K. Aspirin and platelets: The antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin. Thromb. Hemost. 23 (1997) 349-356
104. Sharis P.J., Cannon C.P., and Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann. Intern. Med. 129 (1998) 394-405
105. Shattil S.J., Gao J., and Kashiwagi H. Not just another pretty face: Regulation of platelet function at the cytoplasmic face of integrin alpha Ilb beta 3. Thromb. Haemost. 78 (1997) 220-225
106. Shattil S.J., Kashiwagi H., and Pampori N. Integrin signaling: The platelet paradigm. Blood 91 (1998) 2645-2657
107. Skrzypczak-Jankun E., Carperos V.E., Ravichandran K.G., Tulinsky A., Westbrook M., and Maraganore J.M. Structure of the hirugen and hirulog 1 complexes of alpha-thrombin. J. Mol. Biol. 221 (1991) 1379-1393
108. Stenflo J., Ferlund P., Egan W., and Roepstorff P. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc. Natl. Acad. Sci. USA 71 (1974) 2730-2733
109. Suttie J.W. Synthesis of vitamin K-dependent proteins. FASEB J. 7 (1993) 445-452
110. Tcheng J.E. Glycoprotein IIb/IIIa receptor inhibitors: Putting the EPIC, IMPACT II, RESTORE and EPILOG trials into perspective. Am. J. Cardiol. 78 (1996) 35-40
111. Tcheng J.E., Harrington R.A., Kottke-Marchant K., Kleiman N.S., Ellis S.G., Kereiakes D.J., Mick M.J., Navetta F.I., Smith J.E., Worley S.J., et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrilin in elective coronary intervention: IMPACT Investigators. Circulation 91 (1995) 2151-2157
112. Teitel J.M., and Rosenberg R. Protection of factor Xa from neutralization by the heparin-antithrombin complex. J. Clin. Invest. 71 (1983) 1383-1391
113. ten Cate H., Henny C.P., ten Cate J.W., Buller H.R., Mooy M.C., Surachno S., and Wilmink J.M. Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients. Thromb. Res. 39 (1985) 211-222
114. Tollefsen D.M. Heparin cofactor II. Adv. Exp. Med. Biol. 425 (1997) 35-44
115. Upward J.W., Strong H.A., George C.F., Ogilive B.C., Challenor V., and Conway N. Hypotension in response to iloprost, a prostacyclin analogue. Br. J. Clin. Pharmacol. 21 (1986) 241-243
116. Vane J.R., and Botting R.M. Mechanism of action of aspirin-like drugs. Semin. Arthritis Rheum. 26 (1997) 2-10
117. Von Bonsdorff M., Stiekema J., Harjanne A., and Alapiessa U. A new low molecular weight heparinoid Org 10172 as anticoagulant in hemodialysis. Int. J. Artif. Organs 13 (1990) 103-108
118. Walenga J.M., Pifarre R., Hoppensteadt D.A., and Fareed J. Development of recombinant hirudin as a therapeutic anticoagulant and antithrombotic agent: Some objective considerations. Semin. Thromb. Hemost. 15 (1989) 316-333
119. Weisman H.F., Schaible T.F., Jordan R.E., Cabot C.F., and Anderson K.M. Anti-platelet monoclonal antibodies for the prevention of arterial thrombosis: Experience with ReoPro, a monoclonal antibody directed against the platelet GPIIb/IIIa receptor. Biochem. Soc. Trans. 23 (1995) 1051-1057
120. Weitz J.I., Leslie B., and Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 97 (1998) 544-552
121. White H.D., Aylward P.E., Frey M.J., Adgey A.A., Nair R., Hillis W.S., Shalev Y., Brown M.A., French J.K., Collins R., Maraganore J., and Adelman B. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO): Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation 96 (1997) 2155-2161
122. Wilde M.I., and Markham A. Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 54 (1997) 903-924
123. Wu K.K. Injury-coupled induction of endothelial eNOS and COX-2 genes: a paradigm for thromboresistant gene therapy. Proc. Assoc. Am. Physicians 110 (1998) 163-170
124. Wu K.K. Molecular regulation and augmentation of prostacyclin biosynthesis. Agents Actions 45 Suppl. (1995) 11-17
125. Wu S.M., Cheung W.F., Frazier D., and Stafford D.W. Cloning and expression of the cDNA for human gamma-glutamyl carboxylase. Science 254 (1991) 1634-1636
126. Yamamoto M., Nakagaki T., and Kisiel W. Tissue factor-dependent autoactivation of human blood coagulation factor VII. J. Biol. Chem. 267 (1992) 19089-19094
127. Yamashita T., Yamamoto J., Sasaki Y., and Matsuoka A. The antithrombotic effect of low molecular weight synthetic thrombin inhibitors, argatroban and PPACK, on He-Ne laser-induced thrombosis in rat mesenteric microvessels. Thromb. Res. 69 (1993) 93-100
128. Zoldhelyi P., McNatt J., Xu X.-M., Loose-Mitchell D., Meidell R.S., Clubb Jr. F.J., Buja L.M., Willerson J.T., and Wu K. Prevention of arterial thrombosis by adenovirus-mediated transfer of cyclooxygenase gene. Circulation 93 (1996) 10-17
129. Zwaal R.F., and Schroit A.J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89 (1997) 1121-1132